Nkarta, Inc.

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The firm’s product include NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes, and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the third quarter ended September 30, 2020, and highlighted recent corporate accomplishments.

Nkarta Reports Third Quarter 2020 Financial Results

First Multi-Center Clinical Trial to Investigate an Engineered NK Cell Targeting NKG2D First Multi-Center Clinical Trial to Investigate an Engineered NK Cell Targeting NKG2D

Nkarta Announces Treatment of First Patient in First-in-Human Clinical Trial of Engineered NKG2D-Based NK Cell Cancer Immunotherapy NKX101

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced a preclinical update on NKX019, its investigational allogeneic cancer immunotherapy that uses donor-derived natural killer (NK) cells engineered with a membrane-bound form of IL15 and a chimeric antigen receptor (CAR) targeting the CD19 antigen.

Nkarta Announces Presentation of Preclinical Data on NKX019, Engineered NK Cell Therapy Candidate Targeting CD19, at the Annual Meeting of the Society for Immunotherapy of Cancer

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conferences:

Nkarta Announces November & December 2020 Investor Conference Schedule

Nadir Mahmood, Ph.D. Named to Expanded Role as Chief Financial and Business Officer Alicia J. Hager , J.D., Ph.D. to Join as Chief Legal Officer

Nkarta Announces Leadership Changes

SOUTH SAN FRANCISCO, Calif., Sept.  29, 2020  (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will participate at the following virtual investor conference:

Nkarta Announces October 2020 Investor Conference Schedule

SOUTH SAN FRANCISCO, Calif., Sept.  08, 2020  (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that it will participate at the following virtual investor conference:

Nkarta Announces September 2020 Virtual Investor Conference Schedule

SOUTH SAN FRANCISCO, Calif., Aug.  20, 2020  (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the second quarter ended June 30, 2020, and highlighted recent corporate accomplishments.

Nkarta Reports Second Quarter 2020 Financial Results

Bed Bath & Beyond

Poseida Therapeutics

Akero Therapeutics Inc

GlaxoSmithKline

Perspecta Inc

Trinseo PLC

WESCO

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit.

Notable Insider Buys: Bed Bath & Beyond, Poseida Therapeutics And More

Nkarta Inc. (NASDAQ: NKTX) announced on Tuesday the underwriters for its initial public offering have completely exercised their overallotment option to purchase 2.1 million additional shares.

Biopharmaceutical Company Nkarta Raises $290M In IPO

Nkarta Inc. NKTX, -6.41% said late Tuesday it raised $289.8 million in its recent public offering after underwriters exercised all their options for shares to cover overallotments.

Nkarta raises nearly $290 million in IPO

Underwriters’ Full Exercise of Option Brings Gross Proceeds to $289.8 Million Underwriters’ Full Exercise of Option Brings Gross Proceeds to $289.8 Million

Nkarta Announces Closing of Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares

The Nkarta (NKTX) IPO is underway for the cancer research company and it has it offering 14 million shares on the Nasdaq.
The post Nkarta IPO: 13 Things for Potential NKTX Stock Investors to Know appeared first on InvestorPlace.

Nkarta IPO: 13 Things for Potential NKTX Stock Investors to Know

Shares of Nkarta Inc. tripled out of the gate Friday, after the biotechnology company's initial public offering priced above its expected range.

Nkarta's stock triples out of the gate, then pulls back

Nkarta Inc. priced its initial public offering Friday at $18 a share, above its price range of $16 to $17, selling 14 million shares to raise about $252 million.

Biotech Nkarta prices IPO at $18 a share, above its price range

SOUTH SAN FRANCISCO, July  10, 2020  (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced the pricing of its initial public offering of 14,000,000 shares of common stock at a public offering price of $18.00 per share. Nkarta anticipates total gross proceeds of approximately $252.0 million, before deducting underwriting discounts and commissions and other offering expenses. The shares are expected to begin trading on The Nasdaq Global Select Market on July 10, 2020 under the ticker symbol "NKTX." All shares of common stock are being offered by Nkarta. The offering is expected to close on or about July 14, 2020, subject to customary closing conditions. In addition, Nkarta has granted the underwriters a 30-day option to purchase up to an additional 2,100,000 shares of common stock at the initial public offering price.

Nkarta Announces Pricing of Initial Public Offering

News for Nkarta, Inc. Stock (NKTX)